- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白實(shí)驗(yàn)
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag親和凝膠
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 細(xì)胞核與細(xì)胞漿蛋白抽提試劑盒
- 免疫磁珠
- 蛋白酶抑制劑Cocktail
- 蛋白酶抑制劑Cocktail(DMSO儲液)
- 磷酸酶抑制劑Cocktail
- 細(xì)胞實(shí)驗(yàn)
- Cell Counting Kit-8 (CCK-8)
- 新產(chǎn)品
- 聯(lián)系我們
Home
DNA Damage/DNA Repair
DNA/RNA Synthesis inhibitor
-
HIV inhibitor
-
Autophagy activator
-
Apoptosis related inducer
Hydroxyurea
僅限科研使用
Hydroxyurea
別名: NCI-C04831, Hydroxycarbamide,NSC-32065
Hydroxyurea是一種抗腫瘤藥，通過抑制核苷二磷酸還原酶 ribonucleoside diphosphate reductase 而抑制DNA合成。 Hydroxyurea 可激活凋亡和自噬，并可用于治療HIV感染。
Hydroxyurea Chemical Structure
CAS: 127-07-1
產(chǎn)品質(zhì)控
批次：
純度：
99.95%
99.95
Hydroxyurea相關(guān)產(chǎn)品
| 相關(guān)靶點(diǎn) | tRNA synthetase RdRp DNA synthesis helicase ribonucleotide reductase | 點(diǎn)擊展開 |
|---|---|---|
| 相關(guān)產(chǎn)品 | CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) RK-33 Triapine (3-AP) Carmofur BMH-21 B02 YK-4-279 Bergapten Azaguanine-8 Halofuginone Adenine HCl Tegafur (FT-207) Mizoribine Cyclocytidine HCl Thymidine Nedaplatin APX-3330 Flupirtine maleate Pritelivir (BAY 57-1293) 6-Thio-dG JH-RE-06 TK216 CRT0044876 Adenine Tubercidin Amenamevir Madrasin ML216 PFM01 BC-LI-0186 | 點(diǎn)擊展開 |
| 相關(guān)化合物庫 | FDA藥物庫 天然產(chǎn)物庫 凋亡分子化合物庫 DNA損傷/ DNA修復(fù)化合物庫 細(xì)胞周期化合物庫 | 點(diǎn)擊展開 |
相關(guān)信號通路圖
細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例
| 細(xì)胞系 | 實(shí)驗(yàn)類型 | 給藥濃度 | 孵育時(shí)間 | 活性描述 | 文獻(xiàn)信息(PMID) |
|---|---|---|---|---|---|
| U373-MAGI | Function assay | 500 uM | 2 hrs | Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 500 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection meas, EC50 = 25.8 μM. | 27117260 |
| U373-MAGI | Function assay | 0.5 mM | 2 hrs | Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 0.5 mM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-C | 27117260 |
| U373-MAGI | Function assay | 2 mM | 6 hrs | Reduction in dATP level in human U373-MAGI cells at 2 mM after 6 hrs by LC-MS/MS analysis | 27117260 |
| U373-MAGI | Function assay | 0.5 mM | 2 hrs | Reduction in dCTP level in human U373-MAGI cells at 0.5 mM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis | 27117260 |
| U373-MAGI | Function assay | 2 mM | 2 hrs | Reduction in dCTP level in human U373-MAGI cells at 2 mM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-C | 27117260 |
| U373-MAGI | Function assay | 0.5 mM | 2 hrs | Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 0.5 mM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC | 27117260 |
| U373-MAGI | Function assay | 2 mM | 2 hrs | Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 2 mM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC | 27117260 |
| U373-MAGI | Function assay | 0.5 mM | 2 hrs | Reduction in dCTP level in human U373-MAGI cells at 0.5 mM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC | 27117260 |
| U373-MAGI | Function assay | 2 mM | 2 hrs | Reduction in dCTP level in human U373-MAGI cells at 2 mM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC | 27117260 |
| U373-MAGI | Antiviral assay | 500 uM | Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity at 500 uM incubated for 4 hrs prior to viral infection measured at 72 hrs post infection by flow cytometric analysis | 27117260 | |
| P388 leukemic cell | Proliferation assay | 24-48 h | Antiproliferative activity of compound expressed as concentration that inhibits 50% of growth of P388 leukemic cell suspension from 24 to 48 hr after compound addition, IC50=32 μM | 2709372 | |
| L1210 | Function assay | 48 h | Activity against cultured L1210 leukemic cells was determined in vitro, after 48 h of incubation. Compound dose that causes 16 % inhibition was reported, ID16 = 1.99 μM. | 6319702 | |
| L1210 Leukemia cells | Growth inhibition assay | Concentration required for 50% inhibition of cell growth (L1210 Leukemia), IC50=21.3796 μM | 2991520 | ||
| Burkitt's lymphoma cells | Function assay | Inhibition of [14C]-cytidine incorporation into DNA in Burkitt's lymphoma cells, IC50 = 37.15 μM. | 11405653 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | ||
| 點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Hydroxyurea是一種抗腫瘤藥，通過抑制核苷二磷酸還原酶 ribonucleoside diphosphate reductase 而抑制DNA合成。 Hydroxyurea 可激活凋亡和自噬，并可用于治療HIV感染。 | |
|---|---|---|
| 靶點(diǎn) |
|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06171217 | Recruiting | Sickle Cell Disease|Children |
Children''s Hospital Medical Center Cincinnati|National Heart Lung and Blood Institute (NHLBI) |
October 27 2023 | Phase 2 |
| NCT05909657 | Recruiting | Sickle Cell Disease |
The University of The West Indies |
July 1 2023 | -- |
| NCT05548062 | Recruiting | Polycythemia Vera |
Novartis Pharmaceuticals|Novartis |
March 2 2023 | -- |
| NCT05662098 | Recruiting | Sickle Cell Disease |
Children''s Hospital Medical Center Cincinnati|Jinja Regional Referral Hospital (JRRH) Sickle Cell Clinic Jinja Uganda |
June 16 2022 | Early Phase 1 |
|
化學(xué)信息&溶解度
| 分子量 | 76.05 | 分子式 | CH4N2O2 |
| CAS號 | 127-07-1 | SDF | Download Hydroxyurea SDF |
| Smiles | C(=O)(N)NO | ||
| 儲存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 15 mg/mL ( (197.23 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Water : 15 mg/mL (197.23 mM) Ethanol : Insoluble |
摩爾濃度計(jì)算器 |
|
體內(nèi)溶解配方 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內(nèi)配方計(jì)算器 | |||||
實(shí)驗(yàn)計(jì)算
摩爾濃度計(jì)算器
動物體內(nèi)配方計(jì)算器（澄清溶液）
第一步：請輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計(jì)算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購、運(yùn)輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱[email protected]，直接聯(lián)系到我們。我們會在24小時(shí)內(nèi)盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項(xiàng)
